APA

Tocoian A., Buchan P., Kirby H., Soranson J., Zamacona M., Walley R., Mitchell N., Esfandiari E., Wagner F. & Oliver R. (20160531). First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. : Lupus.

Chicago

Tocoian A, Buchan P, Kirby H, Soranson J, Zamacona M, Walley R, Mitchell N, Esfandiari E, Wagner F and Oliver R. 20160531. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. : Lupus.

Harvard

Tocoian A., Buchan P., Kirby H., Soranson J., Zamacona M., Walley R., Mitchell N., Esfandiari E., Wagner F. and Oliver R. (20160531). First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. : Lupus.

MLA

Tocoian A, Buchan P, Kirby H, Soranson J, Zamacona M, Walley R, Mitchell N, Esfandiari E, Wagner F and Oliver R. First-in-human trial of the safety, pharmacokinetics and immunogenicity of a PEGylated anti-CD40L antibody fragment (CDP7657) in healthy individuals and patients with systemic lupus erythematosus. : Lupus. 20160531.